Solid Tumor Targeting CAR-T Development Services with OFF Switch

Are you confronting the critical challenges of solid tumor immunotherapy, such as the immunosuppressive tumor microenvironment (TME), antigen escape, or severe on-target/off-tumor toxicity? Creative Biolabs' Solid Tumor Targeting CAR-T Development Services with OFF Switch are designed to overcome these hurdles. We leverage advanced synthetic biology and precision gene-editing to engineer allogeneic CAR-T cells with integrated, programmable safety switches. This multi-layered control strategy enables real-time modulation of T cell activity and enhanced tumor penetration, de-risking your pipeline and accelerating the development of safer, more potent, and viable cell therapies.

Introduction

OFF-switch refers to an engineered molecular mechanism that enables precise, rapid, and often reversible termination of CAR-T cell activity upon exposure to specific external stimuli, such as small molecules or light. In CAR-T therapy, the integration of OFF-switches is critical for enhancing treatment safety by mitigating on-target/off-tumor toxicity, managing cytokine release syndrome (CRS), and preventing uncontrolled T cell activation, thereby reducing life-threatening risks while preserving the potential for sustained antitumor efficacy.

Fig.1 OFF-switch adapters for precision regulation of mSA2 universal CAR-T cells.¹

Solid Tumor Targeting CAR-T Development Services with OFF Switch at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Services with OFF Switch are dedicated to advancing next-generation CAR-T therapies for solid tumors, with a core focus on integrating multi-layered molecular safety switches. Our technology platform enables precise and tunable control over therapeutic activity through the synergistic application of the iCas9 suicide gene system, a ganciclovir-activated safety mechanism, and an ADCC-enhancing switch. This multi-tiered safety architecture forms a critical differentiator, designed to overcome the long-standing challenge of balancing efficacy and safety in solid tumor immunotherapy.

Service Packages

We offer a portfolio of customizable safety and efficacy switches to fit your development process.

Our Service Process

Required Starting Materials:

• Target Antigen Sequences or hybridoma cell lines.
• Tumor Cell Lines or primary patient samples.
• Relevant small-molecule drugs for switch validation (if applicable).

Key Steps:

Final Deliverables:

• Comprehensive Final Data Package.
• Validated Master Cell Bank.

Key Advantages

• Customized Synthetic Design: Dedicated consultation for constructing tailored CAR designs and the precise selection of the most suitable OFF-Switch based on your target profile and specific clinical goals.
• Scalable Process Development: Full optimization of the manufacturing process, from donor T cell isolation and gene editing to transduction and cryopreservation, designed for high yield, consistency, and a clear pathway to large-scale production.
• Comprehensive Data Package: Provision of a complete preclinical data set, including in vitro efficacy validation, functional switch kinetics, and stability analysis.

FAQs

Why Choose Us?

We provide comprehensive solid tumor CAR-T development services centered on a dual OFF-switch safety system. Our platform integrates rituximab-responsive depletion switches for emergency intervention and small molecule–regulated protein degradation switches for daily tunability.

Customer Reviews

"Using Creative Biolabs' Solid Tumor Targeting CAR-T Development Services with OFF Switch in our research has significantly facilitated the shift from autologous research and development to an allogeneic, scalable process. The verified TRAC knockout data gave us confidence to move forward with a large donor pool." Dr. Pl*e.

"The integration of Creative Biolabs' Off-Switch system has been transformative for our multiple myeloma research, enabling superior, small molecule-dependent control over CRS. This level of reversible intervention is unmatched by conventional immunosuppressive approaches." Jo***h W.

How to Contact Us?

We excel in developing allogeneic CAR-T therapies by systematically integrating key enabling technologies, including universal cell platforms and multi-tiered safety switches. This integrated approach enables us to deliver comprehensive solid tumor targeting CAR-T solutions with enhanced safety profiles and potent efficacy.

Interested in advancing your solid tumor program with sophisticated safety engineering?

Contact our team to explore collaborative opportunities.

Reference

1. Kvorjak, Michael et al. "Conditional Control of Universal CAR T Cells by Cleavable OFF-Switch Adaptors." ACS synthetic biology vol. 12,10 (2023): 2996-3007. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1021/acssynbio.3c00320.